Severe Community-Acquired Methicillin-Resistant Staphylococcus aureus Endocarditis in a Child With Structurally Normal Heart: a Case Report

2012 ◽  
Vol 65 (5) ◽  
pp. 480-482
Author(s):  
Nadia Barreto Tenorio Aoun ◽  
Ludmila Ferreira Reis Granja ◽  
Camila Furtado Guedes Pinto ◽  
Laila de Moraes Silva ◽  
Paulo R. Benchimol-Barbosa
Keyword(s):  
Staphylococcus Aureus ◽  
Case Report ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Normal Heart ◽  
Methicillin Resistant ◽  
Staphylococcus Aureus Endocarditis

scholarly journals Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis

1998 ◽  
Vol 42 (4) ◽  
pp. 981-983 ◽  
Author(s):  
Glenn W. Kaatz ◽  
Susan M. Seo ◽  
Jeffrey R. Aeschlimann ◽  
Heather H. Houlihan ◽  
Renee-Claude Mercier ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Body Weight ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Rabbit Model ◽  
Glycopeptide Antibiotic ◽  
In Vivo Efficacy ◽  
Methicillin Resistant ◽  
Therapeutic Alternative ◽  
Staphylococcus Aureus Endocarditis

ABSTRACT The in vivo efficacy of LY333328, a new glycopeptide antibiotic, was compared with that of vancomycin by using the rabbit model of left-sided methicillin-resistant Staphylococcus aureusendocarditis. Animals received LY333328 or vancomycin (25 mg/kg of body weight every 24 or 8 h, respectively) for 4 days. These drugs were equally effective in clearing bacteremia and in reducing bacterial counts in vegetations and tissues. We conclude that in this model, LY333328 was microbiologically effective and may be a therapeutic alternative to vancomycin.

Sign in / Sign up

Export Citation Format

Share Document